Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

(2016) Carmen Rodríguez-Cueto et al.   NEUROSCIENCE

Type-2 cannabinoid receptors in neurodegeneration

(2016) Tiziana Bisogno et al.   PHARMACOLOGICAL RESEARCH

Cannabinoids to treat spinal cord injury

(2016) Angel Arevalo-Martin et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

(2016) Yolanda Gómez-Gálvez et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe?

(2015) Demetrios Moris et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

(2015) Francisco Espejo-Porras et al.   Journal of Neuroimmune Pharmacology

Endocannabinoid signalling and the deteriorating brain

(2015) Vincenzo Di Marzo et al.   NATURE REVIEWS NEUROSCIENCE

Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation

(2015) K. Seidel et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

(2015) Javier Fernández-Ruiz et al.   Neurotherapeutics

Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia

(2015) K.L. Eskow Jaunarajs et al.   PROGRESS IN NEUROBIOLOGY

Endocannabinoid signalling in Alzheimer's disease

(2015) Nazia Maroof et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease

(2014) Anabela Silva-Fernandes et al.   Neurotherapeutics

Endocannabinoid-Hydrolysing Enzymes in the Post-Mortem Cerebellum of Humans Affected by Hereditary Autosomal Dominant Ataxias

(2014) Carmen Rodríguez-Cueto et al.   PATHOBIOLOGY

Changes in CB1and CB2receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

(2013) Carmen Rodríguez-Cueto et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dystonia and the cerebellum: A new field of interest in movement disorders?

(2013) Pavel Filip et al.   CLINICAL NEUROPHYSIOLOGY

Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data

(2013) Heike Jacobi et al.   LANCET NEUROLOGY

The anatomical basis of dystonia: Current view using neuroimaging

(2013) Stéphane Lehéricy et al.   MOVEMENT DISORDERS

Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7

(2013) Udo Rüb et al.   PROGRESS IN NEUROBIOLOGY

Brain pathology of spinocerebellar ataxias

(2012) Kay Seidel et al.   ACTA NEUROPATHOLOGICA

Tremor-spectrum in spinocerebellar ataxia type 3

(2012) Cecilia Bonnet et al.   JOURNAL OF NEUROLOGY

Prospects for cannabinoid therapies in basal ganglia disorders

(2011) Javier Fernández-Ruiz et al.   BRITISH JOURNAL OF PHARMACOLOGY

Endocannabinoids and traumatic brain injury

(2011) Esther Shohami et al.   BRITISH JOURNAL OF PHARMACOLOGY

Update on degenerative ataxias

(2011) Thomas Klockgether   CURRENT OPINION IN NEUROLOGY

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease

(2010) Cristina Blázquez et al.   BRAIN

The endocannabinoid system as a target for the treatment of neuronal damage

(2010) Javier Fernández-Ruiz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond

(2010) Alexandra Durr   LANCET NEUROLOGY

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

(2009) Javier Palazuelos et al.   BRAIN

Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

(2009) Onintza Sagredo et al.   GLIA

SCA3: Neurological features, pathogenesis and animal models

(2008) Olaf Riess et al.   CEREBELLUM

Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease

(2008) Sandro Alves et al.   HUMAN MOLECULAR GENETICS

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation

(2008) An-Hsun Chou et al.   NEUROBIOLOGY OF DISEASE